Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -0.34 | - |
| Mar 7, 24 | -0.71 | -0.55 Decreased by -29.09% |
| Nov 1, 23 | -1.14 | -0.36 Decreased by -216.67% |
| Aug 30, 23 | -0.28 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by N/A% | -108.73 M Decreased by -286.31% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -53.03 M Decreased by -80.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |
| Mar 31, 23 | N/A Decreased by N/A% | N/A Increased by +100.00% | - - |
| Dec 31, 22 | 0.00 Decreased by N/A% | -28.15 M Decreased by -4.36% | Decreased by N/A% - |
| Sep 30, 22 | 0.00 Decreased by N/A% | -29.34 M Increased by +83.52% | Decreased by N/A% - |
| Jun 30, 22 | 0.00 Decreased by N/A% | -30.37 M Decreased by -78.54% | Decreased by N/A% - |
| Mar 31, 22 | N/A Decreased by N/A% | -43.04 M Decreased by -181.25% | - - |